These data demonstrate that secretory clusterin, which is frequently up-regulated in breast cancers by common therapies, including anti-estrogens, may play a significant role in tumor growth and metastatic progression by blocking the apoptotic signaling, leading to cell survival and by increasing the ability of cells to survive during one or more phases of the metastatic process. The gene discussed is CLU; the disease is breast carcinoma.